Financial News

Financial Report: Catalent

Cook Pharmica and Accucaps acquisitions drive revenue growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent 3Q Revenues: $627.9 million (+18%) 3Q Earnings: $19.0 million (-27%) YTD Revenues: $1.8 billion (+22%) YTD Earnings: $0.9 million (earnings were $48.0 million YTD17) Comments: Softgel Technologies segment sales were $228.5 million in the quarter, up 9% primarily attributable to the February 2017 Accucaps acquisition. Drug Delivery Solutions revenue was $313.6 million, up 34% primarily attributable to the Cook Pharmica acquisition which contributed 26 percentage points. Excluding th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters